Brief: Pulmatrix Enters Licensing, Development Agreement With Lung Cancer Initiative At Johnson & Johnson

Pulmatrix

02/01/2020 14:05

Jan 2 (Reuters) - Pulmatrix Inc  PULM.O  -
    * ENTERED INTO A LICENSING AND DEVELOPMENT AGREEMENT WITH
THE LUNG
CANCER INITIATIVE AT JOHNSON & JOHNSON
    * UNDER THE TERMS OF AGREEMENT, THE LUNG CANCER INITIATIVE
WILL
PAY A $7.2 MILLION UPFRONT PAYMENT
    * LUNG CANCER INITIATIVE TO PAY $2 MILLION MILESTONE PAYMENT
ON
COMPLETION OF ONGOING PHASE 1B STUDY OF RV1162/PUR1800 IN STABLE
COPD PATIENTS
    * IF LUNG CANCER INITIATIVE EXERCISES OPTION ON
RV1162/PUR1800 &
PORTFOLIO OF KINASE INHIBITORS, CO ELIGIBLE FOR UP TO $91
MILLION IN MILESTONES

Source: http://bit.ly/39BBXka
Further company coverage:  JNJ.N   PULM.O 

 ((Reuters.Briefs@thomsonreuters.com;))